ARLTS1 is a newly characterized tumor suppressor gene located at chromosome 13q14.3 and involved in the pathogenesis of various types of tumors: two single-nucleotide polymorphisms, one of them responsible for protein truncation, were found statistically associated with familial malignancies, whereas DNA hypermethylation and genomic deletions have been identified as a mechanism of ARLTS1 down-regulation in sporadic cancers. We found that in a large portion of lung carcinomas (37%) and in all analyzed lung cancer cell lines, ARLTS1 is strongly down-regulated due to DNA methylation in its promoter region. After its restoration by adenoviral transduction, ARLTS1-negative A549 and H1299 cells underwent apoptosis and inhibition of cell growth. Furthermore, ARLTS1 reexpression significantly reduced the ability of A549 and H1299 to form tumors in nude mice. Finally, we identified f650 transcripts differentially expressed after restoration of ARLTS1 expression in A549 cells, suggesting that various pathways involved in cell survival, proliferation, signaling, and development mediate the effects of wild-type ARLTS1 in a lung cancer system. [Cancer Res 2007; 67(16):7738-45] 
Introduction
ARLTS1 (ARL11, OMIM 609351) is a newly characterized tumor suppressor gene located at chromosome 13q14.3 and involved in the pathogenesis of various types of tumors (1) . It encodes for a small guanine nucleotide binding protein and is a member of the ADP-ribosylation factor (ARF)-ARF-like (ARL) family of the Ras protein superfamily (2, 3) . Several lines of evidence support its proposed suppressor function. First, the G446A (W149X) and T442C (C148R) polymorphisms in ARLTS1 gene have been shown to influence familial cancer risk for B-cell chronic lymphocytic leukemia (B-CLL) and BRCA-1/BRCA-2-negative breast cancers (1, 4, 5) . Second, down-regulation of ARLTS1 was consistently reported after analyzing a small number of CLL and lung cancers (1) and a larger panel of ovarian primary tumors or cell lines (6) . The mechanisms responsible for these low levels of expressions are varied and include promoter hypermethylation or loss of heterozygosity. The chromosomal region 13q14.3 where the gene is located was reported to be deleted in a variety of hematopoietic and solid tumors, including B-CLL, mantle cell lymphomas, multiple myeloma, and myeloid malignancies, and in prostate cancer as well as low-malignant and benign lipomatous tumors (1) . Furthermore, after ARLTS1 restoration by adenoviral transduction, only the negative ovarian TOV-112 cells, but not the OV-90 cells expressing a normal ARLTS1 product, underwent apoptosis and inhibition of cell growth (6) . In addition, ARLTS1 reexpression significantly reduced the tumorigenic potential of TOV-112 cells in nude mice (6) . Here, we reported an expression study on a large panel of lung cancers and investigate by using an adenoviral system the effects of restoration of ARLTS1 expression in lung cancers cells. We found that ARLTS1 has a suppressor function also in this histotype, supporting for a large spectrum of malignancies in which its down-regulation has pathogenetic effects.
Materials and Methods
Northern blot analysis. The analysis was done on filters with human poly(A)+ from several tissues purchased from Clontech. Filters were probed with a cDNA corresponding to the entire coding sequence of ARLTS1 and h-actin hybridization was used to normalize the sample loading.
Homology tree and multiple protein sequence alignments. These were done using the CLUSTALW (text only) program. 5 Twenty-six human members of ARF/ARL family were uploaded 6 and used for the analyses. The homologous genes were found in Mus musculus, Rattus norvegicus, Denio rerio, Drosophila melanogaster, and Arabidopsis thaliana and aligned using the same software.
Cell lines and tissues. Human lung cancer cell lines A549, NCI-H1299, NCI-H460, NCI-H522, Calu-3, NCI-H23, NCI-H1650, NCI-H1573, and SK-MES-1 were obtained from the American Type Culture Collection; HEK293 cells were purchased from Qbiogene. Lung cancer cells were maintained in RPMI 1640 with 10% fetal bovine serum (FBS); HEK293 cells were cultured in DMEM supplemented with 10% FBS. Tumors and corresponding noncancerous tissues were obtained from patients who underwent surgery at the Hospital of the University of Pennsylvania. Tissue samples were excised and immediately stored at À80jC. DNA was extracted from each of the 9 cell lines and from the 27 paired lung tissues according to methods previously described (1) .
Real-time PCR. RNA was extracted with Trizol (Invitrogen Life Technologies, Inc.) following the manufacturer's recommendations. Western blot analysis and antibodies. Proteins were extracted by lysing cells in a Triton extraction buffer containing 10 mmol/L TrisHCl (pH 7.4), 5 mmol/L NaCl, 5 mmol/L EDTA, 10% glycerol, 1% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mg/mL, and 1 mmol/L sodium orthovanadate. Concentrations of proteins in the lysates were measured with the Bio-Rad protein assay reagent (Bio-Rad, Inc.) according to the manufacturer's protocol. Equal amounts of protein (20 Ag) were boiled in Laemmli sample buffer, separated in a 4% to 20% SDS-PAGE gel (Ready Gels, Bio-Rad), and transferred to nitrocellulose membranes (Bio-Rad). Filters were blocked in TBS with 5% skim milk for 2 h. Primary antibodies used in this study were a monoclonal antibody raised against ARLTS1 (1) and antibodies against poly(ADP-ribose) polymerase (PARP), caspase-9, and h-actin (Amersham Biosciences).
Adenovirus preparation. A recombinant adenovirus carrying the ARLTS1 coding sequence under the transcriptional control of a constitutively expressed cytomegalovirus promoter (Ad ARLTS1) was generated using the Adenovator kit according to the manufacturer's procedures (Qbiogene) as previously described (6) . A recombinant adenovirus carrying the green fluorescent protein (GFP) reporter was purchased from Qbiogene and used as a control. Adenoviruses were amplified in HEK293, purified with a cesium chloride gradient, and titrated. A549 and H460 cells were infected with either Ad ARLTS1 or Ad GFP at a multiplicity of infection (MOI) of 50.
Growth curves. Cells (1 Â 10 4 ) were plated in each well of a 12-well plate and infected with either Ad ARLTS1 or Ad GFP at MOI 50. Cells were harvested at regular intervals and counted.
Fluorescence-activated cell sorting analysis. Cells (2 Â 10 4 ) were plated in a six-well plate and infected with Ad ARLTS1 at MOI 50. Cells were harvested 5 days after infection and washed with PBS. Mock-infected cells and cells infected at MOI 50 with Ad GFP served as controls. DNA was stained with propidium iodide (50 mg/mL) and analyzed with a FACScan flow cytometer (Becton Dickinson) interfaced with a Hewlett-Packard computer. Cell cycle data were analyzed with the CELL-FIT program (Becton Dickinson).
Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay. Wild-type, Ad GFP-infected, and Ad ARLTS1-infected NCI-H1299 cells were assessed for the induction of single strand breaks by the terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay using the In Situ Cell Death Detection Kit (Boehringer/Roche) according to the manufacturer's instruction. Cells were grown in four-chambered tissue culture slides. Five days after transduction at MOI 50, the slides were washed with PBS, fixed with paraformaldehyde, permeablized with 0.2% Triton, and incubated with terminal deoxynucleotidyl transferase and fluorescein-dUTP. Slides were then incubated with antifluorescein antibody-alkaline phosphatase conjugate. After exposure to Fast Red substrate (DAKO), cells were visualized by light microscopy. Two hundred cells were counted and the fraction of apoptotic cells was presented as a percentage. The experiment was done in triplicate.
Animal studies. Six-week-old nude mice were obtained from Charles River Laboratories. Animal experiments were conducted under institutional guidelines established for the Animal Facility at the Kimmel Cancer Center. Mock-infected A549 and H460 cells and parental cells infected either with Ad GFP or Ad ARLTS1 (1 Â 10 6 ) at MOI 50 were s.c. injected 24 h after infection into the right flank of nude mice (eight animals each group). The animals were monitored twice weekly for tumor formation for up to 1 month after the injection. The mice were sacrificed and tumors were dissected out and weighed.
Microarray study. Microarray study was done as described (1) . We used a pMV7-ARLTS1 construct because, in respect with the adenovirus, it induced more physiologic levels of reexpression; furthermore, three independent stable clones were analyzed. Detailed methods can be found in the Supplementary data.
Results
Expression of human ARLTS1 in different normal tissues. The analysis of the expression pattern of a gene during adulthood can provide valuable insights about its function. We have analyzed the expression of ARLTS1 gene in different adult tissues by Northern hybridization. The expression of the 2.4-kb ARLTS1 transcript showed a ubiquitous distribution; ARLTS1 gene was predominantly expressed in lymph nodes, spleen, and bone marrow, whereas lower expression was detected in ovary, lung, and liver. Additional transcripts of f1.3 and f5 kb were expressed in the majority of analyzed normal tissues including lung (Fig. 1) . ARLTS1 is highly conserved during evolution. We used the alignments of ARLTS1 cDNA sequence with other 25 human ARF/ ARL homologues to generate a dendogram with sequence similarities: the resulted diagram indicates that the closest homologues of ARLTS1 are ARL14, followed by ARL4D, ARL4C, and ARL4A ( Fig. 2A and B) . Furthermore, we found homologues of ARLTS1 in M. musculus, R. norvegicus, D. rerio, D. melanogaster, and A. thaliana (Fig. 2C) . This finding indicates that this gene is highly conserved among various species during evolution, suggesting an important role for ARLTS1 in eukaryotic cells.
ARLTS1 expression is strongly reduced or absent in lung tumor specimens and lung cancer cell lines. To evaluate ARLTS1 expression levels in human lung cancer, we carried out a real-time PCR on 27 non-small-cell lung cancer tumors (including 12 adenocarcinomas, 9 squamous cell cancers, and 6 with other histology) and their normal paired lung tissues. Among the analyzed tumors, a statistically significant reduction in ARLTS1 expression was observed in 10 (37%) tumor samples [including 50% (6 of 12) of analyzed adenocarcinomas] compared with their normal counterparts, but in none of two nonepithelial analyzed tumors (Fig. 3A and Supplementary Table S1 ). Furthermore, ARLTS1 expression was also assessed with the same approach in a panel of nine lung cancer cell lines. As shown in Fig. 3B , ARLTS1 messenger was slightly reduced in H552 and H1573 cells, strongly reduced in H460 and SK-MES-1 cells, and, finally, virtually absent or extremely reduced in the remaining five cell lines (A549, H1299, Calu-3, H23, and H1650). Taken together, these data indicate that ARLTS1 was expressed at low levels or not expressed at all in more than half of the analyzed cancer samples (19 of 39, 52.7%), meaning that this is an extensive phenomenon in the lung type of cancers. No association with a particular histotype was found, but this study was not designed for this purpose, and a much larger set of samples has to be analyzed to achieve definite conclusions. In two samples, higher levels of expression were present in cancers as in corresponding normal tissues; unfortunately, no other material was available to test if these cases were harboring any of the dysfunctional polymorphisms described in ARLTS1, making the protein less functional in comparison with the normal wild-type. This is the case of the breast cancer MCF7 cells, which express abundantly ARLTS1 but only the truncated version of the protein is present (1, 6).
We recently described hypermethylation of a putative promoter region as a possible mechanism for ARLTS1 down-regulation (1). Therefore, we carried out methylation analyses by bisulfite treatment and correlation analysis with expression levels in three lung cancer cell lines (A549, H1299, and H460), two normal lung samples, and two lymphoblastoid cells. Whereas in all four normal samples the putative ARLTS1 promoter was not hypermethylated and the expression of ARLTS1 was present, in all three analyzed cell lines the lack/reduced levels of expression were concordant Figure 2 Continued. B, sequence alignments for the closest four human homologues; C, sequence alignments for eukaryotic homologues. In white on black background are presented the most conserved amino acids.
with the levels of methylation of the promoter (Supplementary Table S2 ).
Reconstitution of ARLTS1 through a recombinant adenovirus blocks proliferation of human lung cancer cells. To assess the role of ARLTS1 as a therapeutic gene in lung cancer cells, we infected A549 and H1299 cells with a recombinant adenovirus carrying ARLTS1 cDNA (Ad ARLTS1; ref. 6). A recombinant adenovirus for the GFP reporter was used as a control. Cells were infected at MOI 50 and ARLTS1 overexpression in Ad ARLTS1-transduced A549 and H1299 cells was confirmed by Western blot analysis 48 h after infection (Fig. 4A) . ARLTS1 transgene dramatically suppressed the growth rate of both Ad ARLTS1-infected cell lines; conversely, no effects were observed in A549 and H1299 cells infected with Ad GFP at the same MOI after comparison with their parental mock-infected cells (Fig. 4B) .
ARLTS1 overexpression in lung cancer cells induces apoptosis. To evaluate cell cycle perturbations in A549 and H1299 cells virally transduced with Ad ARLTS1, we did a flow cytometric analysis of these cells harvested 5 days after infection at MOI 50. Both A549 and H1299 Ad ARLTS1-infected cells displayed a significant appearance of a sub-G 1 fraction (22.9% and 31.7% in A549-Ad ARLTS1 and H1299-Ad ARLTS1 cells, respectively). No significant alterations in the cell cycle profile were observed in both cell lines infected with Ad GFP compared with noninfected controls (Fig. 5A ) . A TUNEL assay done on H1299 and A549 ARLTS1-overexpressing cells confirmed that the sub-G 1 cell fraction was indeed primarily composed of apoptotic cells (Fig. 5B and data not shown).
We previously showed that A549 cells transfected with an expression vector carrying ARLTS1 cDNA resulted in apoptosis mediated by the activation of the apoptotic intrinsic pathway (1). To evaluate if adenovirally mediated ARLTS1 reconstitution in A549 cells could itself be responsible for triggering the same apoptotic pathway, we did a Western blot with protein lysates from A549 cells infected with Ad ARLTS1 at MOI 50, 96 h postinfection; filters were probed with caspase-9 and PARP antibodies. Both markers are clearly down-regulated in A549 Ad ARLTS1-infected cells compared with controls (Fig. 4A) , confirming the role of the apoptotic intrinsic pathway in the ARLTS1-mediated apoptosis.
Ad ARLTS1 leads to decreased tumorigenicity of human lung cancer cell lines. We finally assessed ARLTS1 tumor suppressor activity also in vivo. Both A549 and H1299 cells were infected with Ad ARLTS1 at MOI 50; 24 h after infection, cells were injected in the right flank of 6-week-old nude mice. As a control, we injected mock-infected cells and cells infected with Ad GFP at MOI 50; three groups of six mice each were used in this study. Mice were Western blot analysis of caspase-9 and PARP in lysates from A549 and H1299 ARLTS1-overexpressing cells. h-Actin was used for sample normalization. B, growth rates of mock-infected, Ad GFP-infected, and Ad ARLTS1-infected A549 (top ) and H1299 (bottom ) lung cancer cells. Points, mean of three different experiments; bars, SD. monitored for tumor appearance for 1 month; mice were then sacrificed and tumors excised and weighed. Statistically significantly smaller tumors (4-fold reduction, P < 0.05) were obtained from cells preinfected in vitro with Ad ARLTS1 compared with their controls in both cell lines, thus showing the ability of ARLTS1 to block tumor formation in preclinical models (Fig. 6) .
The molecular bases of ARLTS1 tumor suppressor effect in A549 lung cancer cell line. To analyze the global molecular changes following A549 cell line stable transfection with ARLTS1, we did a microarray assay with an 18K EST microarray (described in Supplemetary Methods). Three clones transfected with fulllength ARLTS1 were hybridized on microarray and compared with A549 normal gene expression pattern. When compared with untransfected cells, the ARLTS1-transfected cells showed a different expression pattern; in fact, 455 genes were found upregulated whereas 198 were down-regulated after ARLTS1 transfection (Supplementary Table S3 ). A Gene Ontology (GO) analysis of deregulated genes revealed the functions altered after ARLTS1 transfection (Supplementary Table S4 ). The most frequent GO function among the up-regulated genes was ''Developmental process'' (56 times), whereas among the down-regulated genes it was ''Transport'' (26 times), which is in agreement with the intracellular functions of the ARF/ARL proteins in vesicular transport and membrane trafficking (7) .
The highest level of induction was found for neuronal pentraxin 1 (NPTX1; 166 times), a gene exclusively expressed in neurons and mediating probably the uptake of synaptic material (8) . The second most up-regulated gene (f74 times) is DDX3X (also known as DDX3), a DEAD box RNA helicase with tumor growthsuppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, which was recently shown to be a candidate tumor suppressor (9) and to be deregulated in hepatitis virus-associated hepatocellular carcinomas (10) . Ras-induced senescence 1 (RIS-1) gene, which was f55 times more expressed in ARLTS1 stably transfected than wild-type A549 cells, is a candidate tumor suppressor specifically activated during Rasinduced senescence and is also up-regulated by the transcription factor Ets2 (11) . None of the ras genes as well as Ets2 showed significant expression differences in comparison with the wildtype A549 levels, suggesting that ARLTS1 can be involved in this pathway. The gene expressed at lowest levels (reduced f30 times) in transfected clones was Fc fragment of immunoglobulin G binding protein (FCGBP), a gene that may play roles in immune protection and inflammation in the intestine (Supplementary Table S3 ).
Several apoptosis-related mRNAs with correspondent proteins found by Western blotting or by caspase-3 assay to be activated (caspase-9, caspase-3, APAF-1, and PARP) in the present study or in ref. Table S3) .
A further confirmation of microarray results was the observation that ARLTS1 reexpression after 5-aza-2-deoxycytidine treatment of A549 cells has the same effects on the expression of SNAI2 and NPTX1 genes as ARLTS1 transfection ( Supplementary  Fig. S1 ).
Discussion
In the present study, we proved the tumor suppressor effect of ARLTS1 in lung cancers by showing a significant reduction of ARLTS1 levels in about half of the analyzed samples and by proving in vitro the block of proliferation and apoptosis and in vivo the reduced tumorigenic effect after restoration of ARLTS1 expression in defective cells. Furthermore, we investigated at the genome-wide level by microarray the mechanisms associated with these effects and found that significant variation in f650 transcripts is associated with the restoration of ARLTS1 expression. These data expand the spectrum of tissues where ARLTS1 exerts suppressor roles by the addition of lung cancers. It was shown before that the gene is acting in the same way in B-CLL cells and in breast and ovarian cancer cells (1, 6 ).
An uncommon single nucleotide polymorphism in ARLTS1 (i.e., G446A that causes a premature stop codon) has been suggested to be predisposing for familial cancer because it was shown to be more frequent among cancer patients with a family history of cancers, including CLL, pancreatic, melanoma, prostate, and breast, compared with a control population (1, 16) . Furthermore, association of the ARLTS1 Cys148Arg variant with familial breast cancer risk has been also described (5) . Cys148Arg revealed also a statistically significant association with an increased risk of melanoma for heterozygous carriers (17) , whereas G446A was associated with an increased cancer familial aggregation of melanomas (18) . Although significantly associated with familial risk of cancer, ARLTS1 G446A was not found to be more frequently present in sporadic cancers in respect with normal population by several studies, including our initial one (1, 18, 19) .
These data suggest that ARLTS1 could be involved by a distinct pathogenetic mechanism in sporadic cancers. In fact, homozygous or heterozygous deletions at chromosome 13q14.3 are found in a variety of hematopoietic and solid tumors, including B-CLL (20) , mantle cell lymphomas, multiple myeloma, and myeloid malignancies, and in prostate cancer (21) as well as lowmalignant and benign lipomatous tumors (21) (22) (23) . Hypermethylation of putative promoter region located in the immediate 5 ¶ genomic region of the gene was proved to be also associated with low levels of expression in B-CLL, ovarian, breast, and lung cancers (1, 6) .
The exogenous restoration of ARLTS1 gene expression in cancer cell lines with very low levels of expression changes the expression of several hundreds of genes, mainly by overexpression (455 of 653, 70%). Interestingly, among these are 30 transcription factors upregulated (and only 4 down-regulated), and the most frequently found GO function is represented by ''Developmental processes'' (56 up-regulated and 18 down-regulated genes) followed by ''Transport'' (34 up-regulated and 26 down-regulated genes). Furthermore, the expression of several oncogenes including the FOS gene involved in cell growth and/or maintenance, the small GTPase RAB31, or the antiapoptotic BIRC5 gene is induced by ARLTS1 transfection (Supplementary Table S4 ). All these data together suggest that various pathways involved in cell survival, proliferation, signaling, and development mediate the effects of wild-type ARLTS1 in a lung cancer system.
